Barclays has revised its price target for Twist Bioscience (TWST, Financial), reducing it from $58 to $45 while maintaining its Overweight rating for the company's stock. This adjustment comes as part of an earnings preview for the first quarter, specifically focusing on the life science tools and diagnostics sector.
Despite life science tools traditionally being seen as a defensive investment, Barclays has expressed concerns about increasing vulnerabilities. These concerns stem from the potential introduction of pharma-specific tariffs, which could lead to further budget cuts within the industry.
In addition to adjusting Twist Bioscience's target, Barclays has also downgraded its outlook on contract research organizations due to decreased visibility in the market. The firm’s latest assessments underscore the evolving challenges and risks facing companies within the life sciences and related sectors.
